2026 Jos Jonkers: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	106	1142	1017	14	14	408	46431
Medicine	106	6464	6082	246	240	412	46532

Research.com Recognitions

2023 - Research.com Biology and Biochemistry in Netherlands Leader Award

Overview

Jos Jonkers is affiliated with the Antoni van Leeuwenhoek Hospital in the Netherlands. Their research spans the fields of Biochemistry, Genetics and Molecular Biology and Medicine, with a significant focus on Molecular Biology, Oncology, Cancer Research, Genetics, and Immunology.

The main topics of Jos Jonkers's work include:

DNA Repair Mechanisms
PARP inhibition in cancer therapy
Cancer Genomics and Diagnostics
CRISPR and Genetic Engineering
Cancer Cells and Metastasis
Epigenetics and DNA Methylation
BRCA gene mutations in cancer

Jos Jonkers has contributed to several recent papers, including:

"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer" (2020, Annals of Oncology)
"Understanding and overcoming resistance to PARP inhibitors in cancer therapy" (2021, Nature Reviews Clinical Oncology)
"Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency" (2021, Molecular Cell)
"Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts" (2021, Nature Genetics)
"BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers" (2020, Science Translational Medicine)

Frequent co-authors collaborating with Jos Jonkers include:

Marieke van de Ven
Roebi de Bruijn
Lodewyk F.A. Wessels
Catrin Lutz
Jelle Wesseling

Their work has been published predominantly in the following venues:

Cancer Research
bioRxiv (Cold Spring Harbor Laboratory)
Nature
Nature Communications
Molecular Cell

Best Publications

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

Serena Nik-Zainal;Serena Nik-Zainal;Helen Davies;Johan Staaf;Manasa Ramakrishna

2186
Citations
Patient-derived xenograft models: an emerging platform for translational cancer research.

Manuel Hidalgo;Frederic Amant;Andrew V. Biankin;Eva Budinská

1614
Citations
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.

Seth B. Coffelt;Kelly Kersten;Chris W. Doornebal;Jorieke Weiden

1574
Citations
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Jonkers J;Meuwissen R;van der Gulden H;Peterse H

1187
Citations
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

Peter Bouwman;Amal Mahmoud Aly;Jose M. Escandell;Mark Pieterse

1147
Citations
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Sven Rottenberg;Janneke E. Jaspers;Ariena Kersbergen;Eline van der Burg

1085
Citations
Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum

Silvia Marino;Marc Vooijs;Hanneke van der Gulden;Jos Jonkers

1069
Citations
Long-term expanding human airway organoids for disease modeling

Norman Sachs;Angelos Papaspyropoulos;Domenique D. Zomer-van Ommen;Inha Heo

1020
Citations
Patterns of somatic structural variation in human cancer genomes

Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

942
Citations
Replication fork stability confers chemoresistance in BRCA-deficient cells

Arnab Ray Chaudhuri;Elsa Callen;Xia Ding;Ewa Gogola

850
Citations
Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways

Mirjam C. Boelens;Tony J. Wu;Barzin Y. Nabet;Bihui Xu

811
Citations
Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells

Ate Loonstra;Marc Vooijs;H. Berna Beverloo;Bushra Al Allak

720
Citations
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis

Patrick W.B. Derksen;Xiaoling Liu;Francis Saridin;Hanneke van der Gulden

701
Citations
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

Peter Bouwman;Jos Jonkers

669
Citations
Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.

Laurens A. van Meeteren;Paula Ruurs;Catelijne Stortelers;Peter Bouwman

643
Citations
Interrogating open issues in cancer precision medicine with patient-derived xenografts

Annette T. Byrne;Denis G. Alférez;Frédéric Amant;Daniela Annibali

630
Citations
REV7 counteracts DNA double-strand break resection and affects PARP inhibition

Guotai Xu;J. Ross Chapman;Inger Brandsma;Jingsong Yuan

586
Citations
The Shieldin complex mediates 53BP1-dependent DNA repair

Sylvie M. Noordermeer;Sylvie M. Noordermeer;Salomé Adam;Dheva Setiaputra;Marco Barazas

550
Citations
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors

Janneke E. Jaspers;Ariena Kersbergen;Ute Boon;Wendy Sol

530
Citations
Axin and Frat1 interact with Dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1

Lin Li;Huidong Yuan;Carole D. Weaver;Junhao Mao

523
Citations